BONK, INC. quarterly report, Q1 FY2023

Filing identity and reporting period

The supplied filing is Jupiter Wellness, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2023, filed May 12, 2023. It does not appear to be a BONK, INC. filing; verify the issuer and ticker before relying on this summary.

Jupiter Wellness reported two segments: CBD-based skin and wellness products, and theme-park merchandise through SRM Entertainment. The company also describes product development and licensing activities.

Financial results and position

Revenue increased about 55% year over year; gross margin was about 22.0%, versus 16.2%. The lower net loss mainly reflects the absence of the $1.0 million note impairment recorded in Q1 2022 and lower general and administrative expenses. Interest expense increased to $58,552 from $26,102.

At March 31, 2023, cash was $3.74 million, working capital was $4.37 million, current assets were $9.00 million, and current liabilities were $4.64 million. Total assets were $10.91 million and total liabilities $5.10 million. The balance sheet included $2.0 million of related-party convertible notes, $49,416 of SBA loan balance, and lease liabilities totaling about $647,000. The filing reports no cash paid for interest or income taxes during the quarter.

Cash rose $1.81 million during the quarter, principally alongside $3.45 million of net proceeds from the share offering. The company issued 4,315,787 shares, increasing shares outstanding from 22,338,888 at year-end to 26,654,675 at March 31. It also issued 8,631,574 warrants with a $1.00 exercise price; the underlying-share registration statement was not yet effective. The filing reports 24.6 million warrants outstanding at quarter-end.

Changes versus the prior comparable period

• Sales rose from $721,629 to $1.12 million. SRM Entertainment generated most Q1 2023 revenue: $1.09 million, compared with $34,788 attributed to Jupiter Wellness in the segment table.
• Gross profit increased to $246,645 from $117,211, while the consolidated net loss narrowed by about $1.61 million.
• Operating cash use improved to $1.47 million from $2.71 million. The company ended Q1 with more cash than at December 31, 2022, in part because of equity financing.
• Research and development expense declined to $33,148 from $103,025. Inventory decreased to $265,878 from $441,404, while accounts receivable increased to $860,724 from $647,530.

Outlook, risks, contingencies, and unusual items

Management stated that it was experiencing greater product demand than in early 2022, when it said COVID-19 depressed revenue. The filing provides no quantified financial guidance. Management described ongoing development of products including Photocil, JW-700, JW-500, and NoStingz. Photocil had launched in India in Q3 2022; Taisho planned a JW-700 commercial launch in 2024. These are plans and expectations, not assured outcomes.

The company disclosed that accumulated deficit was $51.91 million and that operating cash use remained significant. The financial statement note says these conditions raise substantial doubt about the company’s ability to continue as a going concern. Management also said it expects to continue incurring significant costs for expansion and development.

JWAC stockholders approved a proposed business combination with Chijet Inc. on May 2, 2023. Jupiter Wellness said it hoped to close by May 15, subject to remaining closing conditions. The filing also describes a $300,000 quarter loan to JWAC for shareholder-meeting costs; this is a related-party connection because Jupiter Wellness’s CEO manages the sponsor and is JWAC’s CEO.

The company said disclosure controls and procedures were ineffective, citing a small team and limitations in accumulating and communicating material information. It reported remediation efforts, including hiring experienced personnel and enhancing accounting processes and controls. The filing contains contradictory language elsewhere describing controls as effective; the ultimate stated conclusion is ineffective.

A prior lawsuit involving the company and related parties was dismissed with prejudice in February 2023 after settlement; the company reported no settlement payment. The filing says management was unaware of other pending or threatened litigation expected to materially affect its financial position, results, or liquidity.

The filing contains apparent inconsistencies in certain disclosures: the segment table’s SRM gross-profit figure does not reconcile to SRM revenue and cost of sales; some cash-flow activity labels appear transposed; and the MD&A’s description of comparative-period operating expenses is inconsistent in places with the financial statements. The consolidated statement of operations reports total operating expenses of $1,496,537 in Q1 2023 and $2,978,933 in Q1 2022.

Important facts for investors to verify

• Confirm issuer identity: the provided filing is for Jupiter Wellness, Inc. (JUPW), not BONK, INC.
• Review the going-concern disclosure, cash burn, and available financing against expected operating and development costs.
• Assess dilution and potential warrant exercises, including the warrant registration status and the related-party convertible notes’ maturity and terms.
• Verify the status and closing conditions of the JWAC–Chijet business combination and the financial exposure from related-party funding.
• Reconcile the filing’s segment gross-profit discrepancy, cash-flow classifications, and conflicting disclosure-controls statements against the filed financial statements and any subsequent filings.